Clinical Trial Update: Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B [Phase 3]

View source ↗

Summary

Phase 3 trial investigating combination entecavir and peginterferon for HBeAg-positive immune-tolerant adults with chronic hepatitis B; study terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• ENTECAVIR (ENTECAVIR)
• Peginterferon (Pegylated interferon)

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: Hepatitis B | Phase 3 | Status: TERMINATED | Results posted: 2018-07-03